NASDAQ:EYPT Eyepoint Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.59 -0.01 (-1.66 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$0.57Now: $0.59▼$0.6250-Day Range$0.48MA: $0.59▼$0.7352-Week Range$0.46Now: $0.59▼$2.69Volume878,526 shsAverage Volume1.32 million shsMarket Capitalization$73.99 millionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingEyepoint Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Eyepoint Pharmaceuticals has a forecasted upside of 492.3% from its current price of $0.59.Amount of Analyst CoverageEyepoint Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesEyepoint Pharmaceuticals has received 399 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEyepoint Pharmaceuticals has received 331 “underperform” votes. (Add your “underperform” vote.)Community SentimentEyepoint Pharmaceuticals has received 54.66% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote “Outperform” if you believe EYPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEyepoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyepoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyepoint Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,900.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders35.95% of the stock of Eyepoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.67% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($0.33) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyepoint Pharmaceuticals is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyepoint Pharmaceuticals is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyepoint Pharmaceuticals has a P/B Ratio of 7.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYPT Previous Symbol CUSIPN/A CIK1314102 Webeyepointpharma.com Phone617-926-5000Debt Debt-to-Equity Ratio12.63 Current Ratio4.16 Quick Ratio3.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.36 million Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book7.39Profitability EPS (Most Recent Fiscal Year)($0.48) Net Income$-56,790,000.00 Net Margins-229.34% Return on Equity-452.45% Return on Assets-67.31%Miscellaneous Employees55 Outstanding Shares125,217,000Market Cap$73.99 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $0.59 -0.01 (-1.66 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EYPT News and Ratings via Email Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions How has Eyepoint Pharmaceuticals' stock been impacted by COVID-19? Eyepoint Pharmaceuticals' stock was trading at $1.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYPT stock has decreased by 43.7% and is now trading at $0.5909. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Eyepoint Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Eyepoint Pharmaceuticals. When is Eyepoint Pharmaceuticals' next earnings date? Eyepoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Eyepoint Pharmaceuticals. How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The company earned $4.12 million during the quarter, compared to analysts' expectations of $2.81 million. Eyepoint Pharmaceuticals had a negative net margin of 229.34% and a negative return on equity of 452.45%. View Eyepoint Pharmaceuticals' earnings history. What price target have analysts set for EYPT? 3 Wall Street analysts have issued 12-month price targets for Eyepoint Pharmaceuticals' stock. Their forecasts range from $1.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 492.3% from the stock's current price. View analysts' price targets for Eyepoint Pharmaceuticals. Are investors shorting Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,210,000 shares, an increase of 14.5% from the August 15th total of 1,930,000 shares. Based on an average trading volume of 2,480,000 shares, the short-interest ratio is currently 0.9 days. Currently, 2.7% of the company's shares are sold short. View Eyepoint Pharmaceuticals' Short Interest. Who are some of Eyepoint Pharmaceuticals' key competitors? Some companies that are related to Eyepoint Pharmaceuticals include Harvard Bioscience (HBIO), BioNano Genomics (BNGO), Precipio (PRPO), HTG Molecular Diagnostics (HTGM), BioForce Nanosciences (BFNH), Astrotech (ASTC), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC), DiaSys (DYXC) and PositiveID (PSID). View all competitors. What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Opko Health (OPK), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), Verastem (VSTM) and Dynavax Technologies (DVAX). Who are Eyepoint Pharmaceuticals' key executives? Eyepoint Pharmaceuticals' management team includes the following people: Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)Mr. David J. Price, Chief Financial Officer (Age 56)Mr. Marty Nazzaro, Sr. VP of Operations What is Eyepoint Pharmaceuticals' stock symbol? Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT." Who are Eyepoint Pharmaceuticals' major shareholders? Eyepoint Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bridgeway Capital Management Inc. (0.57%), Jane Street Group LLC (0.35%), Goldman Sachs Group Inc. (0.11%), Bank of America Corp DE (0.09%), UBS Group AG (0.09%) and Highland Capital Management Fund Advisors L.P. (0.08%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View institutional ownership trends for Eyepoint Pharmaceuticals. Which major investors are selling Eyepoint Pharmaceuticals stock? EYPT stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management Fund Advisors L.P.. View insider buying and selling activity for Eyepoint Pharmaceuticals. Which major investors are buying Eyepoint Pharmaceuticals stock? EYPT stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Bridgeway Capital Management Inc., Bank of America Corp DE, UBS Group AG, Goldman Sachs Group Inc., Principal Financial Group Inc., Principal Financial Group Inc., and Endurance Wealth Management Inc.. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, George Elston, Jay S Duker, John B Landis, and Nancy Lurker. View insider buying and selling activity for Eyepoint Pharmaceuticals. How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eyepoint Pharmaceuticals' stock price today? One share of EYPT stock can currently be purchased for approximately $0.59. How big of a company is Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals has a market capitalization of $73.99 million and generates $20.36 million in revenue each year. The company earns $-56,790,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe. What is Eyepoint Pharmaceuticals' official website? The official website for Eyepoint Pharmaceuticals is eyepointpharma.com. How can I contact Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
